SCHEMBL30312011

SCHEMBL30312011

CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.38
▸ DPP4 P27487 1/20 0.35
▸ FAP Q12884 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ OPRD1 P41143 6/20 0.34
▸ OPRM1 P35372 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ REN P00797 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ MME P08473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30567419 0.91 OPRD1 (0.37) BACE1DPP4FAPDPP8DPP9
SCHEMBL30668291 0.85 DPP4 (0.39) BACE1DPP4FAPDPP8DPP9
SCHEMBL30646300 0.84 TERT (0.40) OPRD1OPRM1SMN1; SMN2RENMME
SCHEMBL30052907 0.82 NPSR1 (0.41) DPP4FAPDPP8DPP9DPP7
SCHEMBL11286924 0.81 PDCD1LG2 (0.44) BACE1OPRD1OPRM1
SCHEMBL11286936 0.81 PDCD1LG2 (0.44) BACE1OPRD1OPRM1
SCHEMBL31129093 0.81 NPSR1 (0.38) DPP4FAPDPP8DPP9DPP7
SCHEMBL29355944 0.80 DPP4 (0.47) BACE1DPP4FAPDPP8DPP9
SCHEMBL30123090 0.80 ALDH1A1 (0.41) BACE1DPP4FAPDPP8DPP9
SCHEMBL31461923 0.79 OPRD1 (0.44) OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023057034-A1 FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY ETH Zürich (CH) 2023-04-13 — — WO claimed
WO-2023057034-A1 FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY ETH Zürich (CH) 2023-04-13 — — WO disclosed
Send feedback